SOURCE : NEW18 NEWS
Last Updated:May 22, 2025, 18:14 IST
Sun Pharma Q4 Results: Its consolidated net profit falls 19% YoY to Rs 2,153.93 crore, against a profit of Rs 2,658.74 crore a year ago.
Sun Pharma Dividend 2025.
Sun Pharmaceutical Industries Ltd has recommended a final dividend of Rs 5.50 per equity share of face value Rs 1 each for FY 2024-25. The dividend is subject to shareholder approval at the upcoming annual general meeting (AGM).
The company has fixed Monday, July 7, 2025, as the record date to determine eligible shareholders for the final dividend. If approved at the AGM, the dividend will be paid on or before Friday, August 8, 2025.
Recommended Stories
Sun Pharma reported a 19 per cent YoY decline in its consolidated net profit to Rs 2,153.93 crore for the March 2025 quarter, against a profit of Rs 2,658.74 crore a year ago. Its total revenue from operations, however, increased 8 per cent YoY to Rs 12,958.84 crore from Rs 11,982.90 crore in the year-ago period.
Its R&D investments stood at Rs 816.6 crore during the March 2025 quarter.
Shares of Sun Pharma on Thursday fell by 0.76 per cent to close at Rs 1,718.70 apiece on the BSE.
Dilip Shanghvi, chairman and managing director of Sun Pharma, said, “Our businesses delivered a robust performance for the year, driven by improving market share in India and growth in global speciality. The near-term pipeline in global speciality is promising, with products such as Leqselvi and Unloxcyt — the latter through our recently announced Checkpoint acquisition — offering significant improvements in patient care. We look forward to speciality becoming an increasingly important part of our business.”
- First Published:
May 22, 2025, 18:10 IST
